**Figure 6.** **Screening and validation of the effects of SCARB1 in ccRCC.** (**A**) Differential mRNA expression analysis of 10 CMGs between ccRCC and normal kidney tissues. (**B**) The AUC for SCARB1 in ccRCC cases was 0.9597. (**C**) Differential protein expression analysis of SCARB1 between ccRCC and adjacent cancerous tissues. (**D**) Comparison of mRNA expression levels of SCARB1 between ccRCC and adjacent cancerous tissues; *n* = 30. (**E**) IHC staining of SCARB1 in clinical ccRCC and adjacent cancerous tissues; N: adjacent cancerous tissue; T: ccRCC tissues. (**F**) Comparison of mRNA expression levels of SCARB1 in HK-2 and RCC cell lines by RT-qPCR; *n* = 3. (**G**) The knockdown efficiency of si-SCARB1 was verified by evaluating SCARB1 mRNA expression using RT-qPCR; *n* = 3. (**H**) Comparison of the clone formation ability between negative control groups and SCARB1 knockdown groups in 769-P and A498 cells. Abbreviations: NC: negative control; KD: knockdown; OD: optical density. (**I**, **J**) Cell proliferation curve following transfection of si-SCARB1 in (**I**) 769-P and (**J**) A498 cells. ^{*}*p-*value < 0.05, ^{**}*p-*value < 0.01, ^{***}*p-*value < 0.001.